Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 6068507, Japan.
Department of Otolaryngology-Head and Neck Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, 2-4-20 Ougimaci, Kita-ku, Osaka, 5308480, Japan.
Exp Brain Res. 2021 Feb;239(2):425-433. doi: 10.1007/s00221-020-05970-0. Epub 2020 Nov 19.
The treatment of sensorineural hearing loss (SNHL) may be achieved via the application of a cochlear implant (CI) that allows the electrical stimulation of spiral ganglion neurons (SGNs). Nevertheless, the efficacy of CIs is limited by the degeneration of SGNs following SNHL. Although the application of exogenous neurotrophic factors has been reported to decrease SGN degeneration, non-invasive targeted drug delivery systems are required to achieve effective results. In this study, an SS-cleavable proton-activated lipid-like material [ssPalm; a neutral lipid nanoparticle (LNP)], was loaded with mRNA, and the efficacy of this material as a delivery system was investigated. Our results showed that LNP carrying brain-derived neurotrophic factor (BDNF) mRNA was suitable for the treatment of inner ear diseases, preventing the degeneration of SGNs. In conclusion, this modern nanotechnology-based bioconjugation system, LNP, is a potential non-invasive targeted therapy allowing the delivering biomaterials to specific structures within the inner ear for the treatment of SHNL.
感音神经性听力损失 (SNHL) 的治疗可以通过应用耳蜗植入物 (CI) 来实现,该植入物允许对螺旋神经节神经元 (SGN) 进行电刺激。然而,CI 的疗效受到 SNHL 后 SGN 退化的限制。尽管已经报道了外源性神经营养因子的应用可以减少 SGN 退化,但需要非侵入性的靶向药物输送系统才能获得有效的结果。在这项研究中,使用了一种 SS 可切割的质子激活类脂样材料 [ssPalm;中性脂质纳米颗粒 (LNP)] 来负载 mRNA,并研究了这种材料作为输送系统的功效。我们的结果表明,携带脑源性神经营养因子 (BDNF) mRNA 的 LNP 适合内耳疾病的治疗,可防止 SGN 退化。总之,这种基于现代纳米技术的生物共轭系统 LNP 是一种潜在的非侵入性靶向治疗方法,允许将生物材料递送到内耳的特定结构中,以治疗 SHNL。